In a report released on April 30, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Aurinia Pharmaceuticals (AUPH – Research Report). The company’s shares closed yesterday at $5.20.
According to TipRanks, Schwartz is an analyst with an average return of -2.1% and a 37.68% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Ultragenyx Pharmaceutical, and Applied Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aurinia Pharmaceuticals with a $10.00 average price target.
Based on Aurinia Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $45.1 million and a GAAP net loss of $26.88 million. In comparison, last year the company earned a revenue of $28.44 million and had a GAAP net loss of $26.05 million
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AUPH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aurinia Pharmaceuticals (AUPH) Company Description:
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
